Literature DB >> 25400380

Recurrent malignant pheochromocytoma with unusual omental metastasis: (68)Ga-DOTANOC PET/CT and (131)I-MIBG SPECT/CT scintigraphy findings.

Saurabh Arora1, Krishan Kant Agarwal1, Sellam Karunanithi1, Madhavi Tripathi1, Rakesh Kumar1.   

Abstract

Pheochromocytomas are rare catecholamine-secreting tumors derived from the sympathetic nervous system. The most common sites of metastasis for pheochromocytoma or extra-adrenal paraganglioma are lymph nodes, bones, lungs, and liver. Patients with known or suspected malignancy should undergo staging with computed tomography (CT) or magnetic resonance imaging as well as functional imaging (e.g. with (123)I/(131)I-MIBG ((131)I-metaiodobenzylguanidine) and (68)Ga-DOTANOC ((68)Ga-labeled [1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid]-1-NaI3-octreotide) positron emission tomography (PET)/CT) to determine the extent and location of disease. We present a case of recurrent malignant pheochromocytoma with unusual site of metastasis in omentum, which was positive on (68)Ga-DOTANOC PET/CT and (131)I-MIBG single-photon emission computed tomography (SPECT/)/CT scintigraphy.

Entities:  

Keywords:  131I-MIBG; 68Ga-labeled [1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid]-1-NaI3-octreotide; Single-photon emission computed tomography/computed tomography; malignant pheochromocytoma; positron emission tomography/computed tomography

Year:  2014        PMID: 25400380      PMCID: PMC4228604          DOI: 10.4103/0972-3919.142654

Source DB:  PubMed          Journal:  Indian J Nucl Med        ISSN: 0974-0244


  7 in total

1.  Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.

Authors:  G Kaltsas; M Korbonits; E Heintz; J J Mukherjee; P J Jenkins; S L Chew; R Reznek; J P Monson; G M Besser; R Foley; K E Britton; A B Grossman
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

2.  Mesenteric paraganglioma: report of a case.

Authors:  Akitoshi Kudoh; Yoshihiro Tokuhisa; Katsuhiko Morita; Sakurao Hiraki; Shintarou Fukuda; Nobuo Eguchi; Takako Iwata
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

3.  Mesenteric paraganglioma: a case report and review of the literature.

Authors:  Shabnam Jaffer; Noam Harpaz
Journal:  Arch Pathol Lab Med       Date:  2002-03       Impact factor: 5.534

4.  Prospective evaluation of ⁶⁸Ga-DOTA-NOC PET-CT in phaeochromocytoma and paraganglioma: preliminary results from a single centre study.

Authors:  Niraj Naswa; Punit Sharma; Aftab Hasan Nazar; Krishan Kant Agarwal; Rakesh Kumar; Ariachery C Ammini; Arun Malhotra; Chandrasekhar Bal
Journal:  Eur Radiol       Date:  2011-10-05       Impact factor: 5.315

5.  Can quantification of VMAT and SSTR expression be helpful for planning radionuclide therapy of malignant pheochromocytomas?

Authors:  Lars Kölby; Peter Bernhardt; Viktor Johanson; Bo Wängberg; Andreas Muth; Svante Jansson; Eva Forssell-Aronsson; Ola Nilsson; Håkan Ahlman
Journal:  Ann N Y Acad Sci       Date:  2006-08       Impact factor: 5.691

6.  [An autopsy case of extra-adrenal malignant pheochromocytoma].

Authors:  Y Sunaga; N Taniguchi; K Hayashi; M Koito; M Inada; N Oyaizu; N Shikata
Journal:  Gan No Rinsho       Date:  1990-09

7.  The management of benign and malignant pheochromocytoma and abdominal paraganglioma.

Authors:  E Edström Elder; A-L Hjelm Skog; A Höög; B Hamberger
Journal:  Eur J Surg Oncol       Date:  2003-04       Impact factor: 4.424

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.